Disclaimer

The website is targeted at investors qualifying as professional investors under MiFID (Directive 2004/39/EU) only. Retail investors are therefore kindly asked to leave this website.

The website and its content is not intended for US Persons, who are kindly asked to leave the website as well.

The content of the website is for information purposes only. The information does not constitute, and shall not be considered as, an offer or invitation to purchase or sell any of the products or services mentioned on the website. The information, calculations etc. on the website shall not be considered investment advice or requests to engage in investment operations.

All reasonable precautions have been taken to ensure the correctness and accuracy of the information available through the website. However, the correctness and accuracy is not guaranteed and C WorldWide Management Fondsmaeglerselskab A/S accepts no liability for any errors, spelling mistakes or omissions. Neither is C WorldWide Management Fondsmaeglerselskab A/S responsible for the suitability of the information on or the content of the website. The information on the website may be amended by C WorldWide Management Fondsmaeglerselskab A/S at any time without notice.

The website and its content has been prepared in accordance with Danish law and the information provided may not satisfy the laws of any other country.

Past performance is not a reliable indicator of future performance.

By accepting, I confirm that I am a professional investor, and that I have understood the terms of use.

Leave
Accept
ⓒ C WORLDWIDE ASSET MANAGEMENT FONDSMAEGLERSELSKAB A/S | DAMPFAERGEVEJ 26 | DK-2100 COPENHAGEN | CVR: 78 42 05 10

INVESTMENT PHILOSOPHY

The investment objective of the C WorldWide Biotechnology fund is to seek capital growth by investing in equities in the biotechnology/bioscience area, including companies with activities in the areas of drug delivery, drug discovery, therapeutics, enabling technologies and diagnostics.

Kompas

Biotech is a research-intensive sector currently in an era of new discoveries and scientific progress. The strategy invests primarily in fast-growing smaller research and pharma companies, which are underanalyzed compared to the bigger ones and consequently more difficult to value. Patent expirations among the bigger companies drive demand. Expiring patents lead to shrinking profits and in order to compensate for this, new products are needed. Smaller biotech companies with drugs under development benefit from this, and the number of new drugs under development is steadily increasing. The fund may be leveraged up to 25 per cent of the value of its net assets for investment purposes.